---
title: "Burning Rock Biotech Director Purchased Shares Worth Over $6.1M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291549820.md"
description: "Han Yusheng, a Director, reported multiple purchases of Burning Rock Biotech ordinary shares represented by American depositary shares. The weighted average price paid per ADS across the seven transactions was $8.4567. The total purchase amount reported was $6,182,171. Han Yusheng directly owns 18,404,086 ADSs following the reported transactions.Reporter NameHan YushengRelationshipDirectorTypePurchaseAmount$6,182,171SEC FilingForm 4DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC."
datetime: "2026-07-02T12:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291549820.md)
  - [en](https://longbridge.com/en/news/291549820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291549820.md)
generator: "portal-rs"
---

# Burning Rock Biotech Director Purchased Shares Worth Over $6.1M

Han Yusheng, a Director, reported multiple purchases of Burning Rock Biotech ordinary shares represented by American depositary shares. The weighted average price paid per ADS across the seven transactions was $8.4567. The total purchase amount reported was $6,182,171. Han Yusheng directly owns 18,404,086 ADSs following the reported transactions.

Reporter Name

Han Yusheng

Relationship

Director

Type

Purchase

Amount

$6,182,171

SEC Filing

Form 4

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BNR.US](https://longbridge.com/en/quote/BNR.US.md)

## Related News & Research

- [Burning Rock Biotech director Han Yusheng reports $6.42 million ADS purchase](https://longbridge.com/en/news/291547634.md)
- [Agriculture & Natural Solutions Acquisition Received Notice of Delisting](https://longbridge.com/en/news/296272312.md)
- [Hansa Biopharma files confidential SEC draft for potential Nasdaq ADS listing](https://longbridge.com/en/news/296569331.md)
- [Ant CEO: Agentic AI Commerce to Boom in Next 6-12 Mths](https://longbridge.com/en/news/296095577.md)
- [Nocera flags prior financial statements as unreliable, files restatement in SEC amendment](https://longbridge.com/en/news/296145907.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**